HIV-1 Viremia and Cancer Risk in 2.8 Million People: The South African HIV Cancer Match Study

南非280万人的HIV-1病毒血症与癌症风险:HIV癌症匹配研究

阅读:1

Abstract

BACKGROUND: Most research on human immunodeficiency virus-1 (HIV-1) viremia and cancer risk is from high-income countries. We evaluated the association between HIV-1 viremia and the risk of various cancer types among people with HIV (PWH) in South Africa. METHODS: We analyzed data from the South African HIV Cancer Match study, based on laboratory measurements from the National Health Laboratory Service and cancer records from the National Cancer Registry from 2004 to 2014. Using Cox proportional hazards models, we estimated hazard ratios (HR) for cancer incidence per unit increase in time-updated Log10 HIV-1 RNA viral load copies/mL. We created partially adjusted (sex, age, calendar year) and fully adjusted models (additionally including time-updated CD4 count). RESULTS: We included 2 770 200 PWH with 10 175 incident cancers; most common were cervical cancer (N = 2481), Kaposi sarcoma (N = 1902), breast cancer (N = 1063), and non-Hodgkin lymphoma (N = 863). Hazard ratios for the association of HIV-1 viremia and cancer risk changed after partial and full adjustment and were generally attenuated for infection-related cancers but tended to increase for infection-unrelated cancers. In the fully adjusted model, HIV-1 viremia was associated with an increased risk of Kaposi sarcoma (HR per unit increase in Log10 HIV-1 RNA viral load: 1.38; 95% confidence interval [CI], 1.35-1.42), leukemia (HR: 1.28; 95% CI, 1.13-1.45), non-Hodgkin lymphoma (HR: 1.24; 95% CI, 1.19-1.29), conjunctival cancer (HR: 1.19; 95% CI, 1.11-1.25), and colorectal cancer (HR: 1.11; 95% CI, 1.02-1.21). Associations with other cancer types were weaker or absent. CONCLUSIONS: Our findings underline the importance of sustained viral suppression for cancer prevention among PWH in South Africa.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。